This is a the United States news story, published by Yahoo, that relates primarily to Novo Nordisk news.
For more the United States news, you can click here:
more the United States newsFor more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
loss drug Wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weekly prescriptions news, prescriptions news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Novo NordiskReuters
•80% Informative
Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States .
CEO Lars Fruergaard Jorgensen said the slower pace of weekly prescriptions in the last couple of months was due to lower starter doses being supplied into the market.
VR Score
90
Informative language
94
Neutral language
86
Article tone
semi-formal
Language
English
Language complexity
53
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links